Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last €16.43 EUR
Change Today -0.38 / -2.26%
Volume 173.8K
ALM On Other Exchanges
As of 11:38 AM 02/11/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

General Mitre, 151

Barcelona, 08022


Phone: 34 93 291 30 00


Almirall, S.A., a pharmaceutical company, researches, develops, manufactures, and markets proprietary and licensed medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections; and gastrointestinal diseases, such as irritable bowel syndrome, as well as for pain. Its products include LAS100977, a potent bronchodilator, which is in phase IIa clinical trial for the treatment of asthma and chronic obstructive pulmonary disease (COPD); LAS190792, a dual long-acting muscarinic antagonist ß2 agonist that is in Phase I clinical for treating COPD; and LAS40464, an aclidinium bromide and formoterol for the treatment of COPD. The company also develops LAS41004, a compound that is in Phase II clinical trials for the treatment of psoriasis and/or atopic dermatitis; LAS41008, which is in Phase III clinical trial for treating psoriasis; and Sativex, an oromucosal spray is in Phase III clinical trial for the treatment of spasticity in patients with multiple sclerosis. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALM:SM €16.43 EUR -0.38

ALM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Innoviva Inc $11.13 USD +0.20
Ironwood Pharmaceuticals Inc $8.08 USD +0.19
Nektar Therapeutics $11.32 USD +0.15
Santen Pharmaceutical Co Ltd ¥1,600 JPY -97.00
Sucampo Pharmaceuticals Inc $11.93 USD +0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation ALM Industry Range
Price/Earnings 6.1x
Price/Sales 3.8x
Price/Book 2.1x
Price/Cash Flow 5.2x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALMIRALL SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at